Loading...
•
Mar 31, 2022
Corcept Therapeutics Q1 2022 Earnings Report
Reported first quarter financial results and provided a corporate update.
Key Takeaways
Corcept Therapeutics reported a revenue of $93.7 million for the first quarter of 2022, compared to $79.4 million in the first quarter of 2021. Diluted net income per share was $0.20, compared to $0.18 in the first quarter of 2021. The company reiterated its 2022 revenue guidance of $400 – $430 million.
First quarter revenue reached $93.7 million, up from $79.4 million in Q1 2021.
The company reaffirmed its 2022 revenue guidance, projecting between $400 and $430 million.
Diluted net income per share increased to $0.20, compared to $0.18 in the same period last year.
Cash and investments increased by $32.3 million during the quarter, reaching $368.1 million.
Forward Guidance
Corcept Therapeutics expects continued growth and reiterated its 2022 revenue guidance of $400 – $430 million.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...